IMPORTANT: Read the Prep & Administration Guide for proper handling, reconstitution (if applicable), and administration technique. Mistakes here can compromise your research.
KPV (Oral)
KPV is a tripeptide (Lys–Pro–Val) derived from the C-terminal sequence of α-melanocyte-stimulating hormone (α-MSH). It has been studied for anti-inflammatory and immunomodulatory effects, particularly in gastrointestinal and dermatologic inflammatory models. Unlike full-length melanocortin peptides, KPV may exert anti-inflammatory effects with minimal pigmentation activity.
Dosing Protocols
— 10 mg Vial —
Reconstitute: Add 3.0 mL bacteriostatic water → ~3.33 mg/mL concentration. Typical daily range: 200–500 mcg once daily (gradual titration recommended). Easy measuring: At 3.33 mg/mL, 1 unit = 0.01 mL ≈ 33.33 mcg on a U-100 insulin syringe. Storage: Lyophilized: freeze at −20 °C or below; reconstituted: refrigerate at 2–8 °C, use within 30 days, avoid freeze-thaw cycles.
Schedule: Daily subcutaneous injections for 8–12 weeks (extend to 16 weeks if desired).
Cycle Length: 8–12 weeks; optional extension to 16 weeks under monitoring.
Goal: Support reduction of systemic inflammation and modulate immune responses without melanotropic effects.
Frequency: Inject once daily subcutaneously.
Phase
Dose
Syringe (U-100)
Week 1
200 mcg
6 units (0.06 mL)
Week 2
300 mcg
9 units (0.09 mL)
Week 3
400 mcg
12 units (0.12 mL)
Weeks 4–8
500 mcg
15 units (0.15 mL)
Benefits
Anti-inflammatory signaling in intestinal epithelial and immune-cell models (preclinical).
Studied in models of colitis and inflammatory bowel disease as a potential mucosal-protective agent (preclinical).
May reduce pro-inflammatory cytokines (e.g., TNF-α, IL-6) in experimental systems.
Investigated for skin inflammation and barrier-supportive effects in topical/oral research contexts.
Potential modulation of NF-κB–related inflammatory pathways (mechanistic).
Mechanism of Action
KPV is linked to α-MSH biology and has been reported to modulate inflammatory signaling, including downregulation of NF-κB activation and decreased production of pro-inflammatory cytokines. Some effects may involve melanocortin receptor pathways or receptor-independent immunomodulation depending on the model. In gut-focused research, KPV has been studied for effects on epithelial integrity and immune-cell activation.
Side Effects
Potential adverse effects reported in literature and/or anecdotally include:
GI upset (cramping, nausea) in some users.
Headache.
Fatigue.
Allergic reactions are possible (peptide).
Side Effect Management
Start with lower doses and increase gradually.
If GI upset occurs, split dosing and take with food.
Discontinue if rash, swelling, or allergic symptoms occur.
Ensure product purity; impurities can drive reactions.
Contraindications
Pregnancy or breastfeeding.
Known hypersensitivity to peptide products.
Active severe infection or significant immunosuppression without oversight (immune-modulating effects).
Research Citations
PubMed-linked citations for verification. Many studies are preclinical (animal/in-vitro).
Tripeptide KPV inhibits NF-κB activation and reduces intestinal inflammation in experimental colitis. J Immunol. 2002.PMID: 12165559 (doi: 10.4049/jimmunol.169.2.718)
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).
